( May 7, 2026, 1:57 PM EDT) -- ST. LOUIS — A ruling by the Fifth Circuit U.S. Court of Appeals that granted Louisiana’s motion to stay the U.S. Food and Drug Administration’s 2023 decision that removed the in-person dispensing requirement for mifepristone, one of two drugs used to induce early termination of pregnancy, bolsters arguments by Missouri, Idaho and Kansas that a federal court in Missouri should deny the FDA’s request to stay the case pending in that court and conclude that the states have standing, the states contend in a notice of supplemental authority....